Archive for the ‘unreliable findings’ Category
AAPS PharmSciTech, a journal of the American Association of Pharmaceutical Scientists, has retracted a 2013 paper by a group from India. The reason appears to be manipulated data, although the wording of the notice leaves that open to interpretation.
The article, “Design and Formulation Technique of a Novel Drug Delivery System for Azithromycin and Its Anti-Bacterial Activity Against Staphylococcus aureus,” was written by a trio of researchers at the Center for Nanobiotechnology at VIT University in Vellore.
Blood has retracted two 2013 illustrations of red cells by researchers from South Africa and the United States because, somewhat confusingly, they didn’t conform to the journal’s criteria for publishing such material.
Living Cell Technologies (LCT), a biotech company headquartered in Australia, has retracted a 2011 paper purporting to show that their product reversed Parkinson’s symptoms in rats after “being unable to reconfirm their reported results and a possible deviation from the protocol.”
The debate over the retraction of a highly controversial paper on the effects of GMOs on rats continues unabated. This week, Adriane Fugh-Berman and Thomas Sherman wrote on the Hastings Center website that Read the rest of this entry »
We have a second retraction from a group of neuroscience researchers in Belgium who discovered fatal errors in their work on how the brain sets about the task of reading written language. Spoiler alert: Turns out those errors weren’t errors after all.
As we reported back in May, the group, from the University of Leuven, was unable to replicate certain fMRI findings in a November 2012 article in Neuroscience. At the time, Hans P. Op de Beeck, who led the group, told us: Read the rest of this entry »
As we wrote in 2012: Read the rest of this entry »
A group of Swiss neurologists have lost their 2013 article in Frontiers in Human Neuroscience after reporting that their data were rendered null by coding errors.
The article, “Spontaneous pre-stimulus fluctuations in the activity of right fronto-parietal areas influence inhibitory control performance,” purported to find that: Read the rest of this entry »
Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.